Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Tango Therapeutics's Enterprise Value is $2,680.22 Mil.
Tango Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-143.90 Mil. Therefore, Tango Therapeutics's EV-to-OCF for today is -18.63.
The historical rank and industry rank for Tango Therapeutics's EV-to-OCF or its related term are showing as below:
TNGX'
s EV-to-OCF Range Over the Past 10 Years
Min: -38.61 Med: -4.01 Max: 1.16
Current: -18.63
During the past 6 years, the highest EV-to-OCF of Tango Therapeutics was 1.16. The lowest was -38.61. And the median was -4.01.
TNGX's EV-to-OCF is ranked better than 80.91% of 1404
companies
in the Biotechnology industry
Industry Median: -3.37
vs TNGX: -18.63
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tango Therapeutics's PE Ratio (TTM) for today is calculated as:
Tango Therapeutics's share price for today is $21.74.
Tango Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.838.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tango Therapeutics EV-to-OCF Related Terms
Tango Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Tango Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tango Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tango Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tango Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Tango Therapeutics's EV-to-OCF falls into.
Tango Therapeutics's current Enterprise Value is $2,680.22 Mil.
Tango Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-143.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tango Therapeutics (TNGX) has a EV-to-OCF of -18.63 as of Sep. 21, 2026. According to the industry distribution chart, Tango Therapeutics ranks #268 out of 1404 companies in the Biotechnology industry, placing it in the top 19.1%.
Is Tango Therapeutics' EV-to-OCF too high?
Tango Therapeutics' current EV-to-OCF is -18.63. Based on the distribution chart, Tango Therapeutics ranks #268 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tango Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tango Therapeutics' EV-to-OCF compare to IDYA and LEGN?
According to the Biotechnology industry distribution chart, Tango Therapeutics ranks #268 out of 1404 companies for EV-to-OCF. This places Tango Therapeutics in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Tango Therapeutics's current EV-to-OCF is -18.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tango Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Tango Therapeutics (TNGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.41, compared to a current price of $21.74 — trading 108.8% above its estimated fair value. The current EV-to-OCF is -18.63. Tango Therapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Tango Therapeutics (TNGX), the current EV-to-OCF is -18.63 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tango Therapeutics (TNGX) Overvalued in 2026?
Based on GuruFocus' analysis, Tango Therapeutics stock appears to be overvalued.
The current stock price of $21.74 is trading 108.8% above its estimated GF Value™ of $10.41.
GuruFocus considers Tango Therapeutics to be Significantly Overvalued.
Key valuation signals for TNGX:
EV-to-OCF: -18.63
GF Value™: $10.41 vs. price of $21.74 (108.8% above fair value)
No single metric tells the full story. See the TNGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
54GF Score
Get the complete analysis for TNGX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNGX has been successfully added to your 
